dsm-firmenich Completes Stake Sale in Feed Enzymes Alliance
dsm-firmenich, a leader in the realms of nutrition, health, and beauty, has announced the successful completion of its sale of a significant stake in the Feed Enzymes Alliance to the international biosolutions company Novonesis. This strategic move, which facilitated a transaction worth €1.5 billion, marks a pivotal development for dsm-firmenich.
Transaction Overview
This significant transaction concluded with dsm-firmenich receiving approximately €1.4 billion in cash after deducting transaction costs. Such a large cash influx is poised to enhance the company’s financial position, providing opportunities for further growth and innovation in its product offerings.
Strategic Importance of the Sale
By divesting from the Feed Enzymes Alliance, dsm-firmenich is strategically repositioning itself to focus on its core operations and innovations within the nutrition, health, and beauty sectors. This sale allows the company to allocate resources more effectively, driving its commitment to sustainability and advancing its comprehensive range of solutions.
About Novonesis
Novonesis stands out as a global leader in providing biosolutions and is expected to leverage the stake in Feed Enzymes Alliance for further advancements. Their commitment to innovative solutions and sustainability aligns closely with the principles upheld by dsm-firmenich, making this partnership beneficial for both parties.
The Vision of dsm-firmenich
Founded in Switzerland, dsm-firmenich is listed on Euronext Amsterdam and operates in nearly 60 countries around the world, boasting impressive revenues that exceed €12 billion. With a dedicated global workforce of around 30,000 employees, the company is anchored in its vision to provide essential products that foster well-being and sustainability. Their innovative capabilities ensure they are always pushing the boundaries to offer vital nutrients, flavors, and fragrances that meet the needs of today’s population.
Commitment to Sustainability
Sustainability is a vital aspect of dsm-firmenich’s operations, influencing every decision made within the company. With natural and renewable ingredients at the forefront of their product development, they are dedicated to reducing their environmental footprint while promoting healthier choices for consumers and communities alike.
Future Opportunities
The completion of this sale heralds new opportunities for dsm-firmenich to invest in innovative research and development projects. By redirecting their focus and resources, they aim to enhance their product range and explore new market segments, ensuring they remain at the forefront of the nutrition and health industry.
Company Contact Information
Media Relations
Robin Roothans
tel. +41 (0)79 280 03 96
e-mail media@dsm-firmenich.com
Investor Relations
Dave Huizing
tel. +31 (0)88 425 7306
e-mail investors@dsm-firmenich.com
Frequently Asked Questions
What is the significance of the sale for dsm-firmenich?
The sale allows dsm-firmenich to enhance its financial resources, enabling further investment in innovation and sustainability initiatives.
Who is Novonesis?
Novonesis is a global leader in biosolutions, known for its commitment to innovation and sustainability, which aligns with dsm-firmenich’s values.
How much cash did dsm-firmenich receive from the sale?
dsm-firmenich received approximately €1.4 billion net in cash following the transaction.
What is the primary focus of dsm-firmenich?
The company focuses on nutrition, health, and beauty, providing vital nutrients and solutions with an emphasis on sustainability.
How does this sale impact the company's future?
This strategic divestment provides dsm-firmenich the opportunity to focus on core operations, driving growth and enhancing their product offerings.